VERA / Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting

The heavy selling pressure might have exhausted for Vera Therapeutics, Inc. (VERA) as it is technically in oversold territory now. In addition to this more_horizontal

Vera Therapeutics, Inc. (VERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combi more_horizontal

Vera Therapeutics, Inc. (VERA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong ag more_horizontal

Informational poster for ORIGIN 3 Pivotal Phase 3 study evaluating atacicept in IgA Nephropathy (IgAN) Additional analysis of week 36 data from Phase more_horizontal

Vera Therapeutics, Inc. (VERA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This mi more_horizontal

Vera Therapeutics revealed 36-week efficacy and safety findings of its Phase IIb ORIGIN clinical study of atacicept for IgAN at the 60th European Rena more_horizontal

Vera Therapeutics, Inc. is trying to develop an old molecule it licensed from Merck & Co., Inc. Trials conducted years earlier produced unimpressive r more_horizontal

The company's lead therapy, Atacicept, is faring well in a phase 2b trial. Vera Therapeutics is already recruiting patients for a phase 3 trial for At more_horizontal